GB Sciences, Inc. (OTCQB:GBLX)

GB Sciences, Inc. (OTCQB:GBLX) is a phytomedical research and biopharmaceutical drug development company. Our goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures for a variety of conditions. GB Sciences’ novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 10 US and 35 international patent-pending applications. In our drug development pipeline, we have four preclinical stage programs, and our lead Parkinson’s disease therapeutic program is being prepared for a First-in-Man clinical trial.

Upcoming Events

GB Sciences presenting at TMED July 12, 2021
GB Sciences presenting at TMED July 12, 2021

Most Recent Investor Presentation

GB Sciences’ Drug Development Programs

Letter to Shareholder's

GBLX Stock Price

The GBLX stock price will be updated periodically, but there may be a lag with respect to real-time stock quotes

SEC Filings for GB Sciences, Inc.

Latest News from GB Sciences

GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief

GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform

Media Contact

Alexis Quintal

alexis@newswire.com